Transaction · 0001415889-24-000608

Megna Michael R

Megna Michael R, CAO, reported an open-market or private sale at Kiniksa Pharmaceuticals, Ltd. involving 16670.000000 shares for an estimated $319563.90. Reported holdings after the transaction were 17005.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCAO
KNSAKiniksa Pharmaceuticals, Ltd.
Filing timeJan 04
Trade dateJan 02, 2024
Filing · SECView on SEC
InsiderProfile

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
—
Pre-filing
1mo ago1w ago1d ago
Returns since
7d30d90d180d1y

KNSA price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
KNSA since 2024-01-04Filed 974 days ago · 30 days of pre-filing context shaded
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001415889-24-000608
Class A Common Share
Transaction date
Jan 02, 2024
Filed Jan 04, 2024, 04:30 PM · 2d delay
Shares
16.6k sh
$1.91k per share
Estimated value
-$31.9M
Computed from shares × price
Holdings after
17.0k sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $10.0MLarge $100M
Direct Ownership Large Holdings Reduction 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

CHIEF ACCOUNTING OFFICER

Officer YesDirector No10% NoOther No
Footnotes & amended
  1. F1

    This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on May 5, 2023.

  2. F2

    This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.13 to $19.43. The price reported in this column reflects a weighted average sales price. Upon reques…

  3. F3

    This option is fully vested and exercisable.

Original filing · 0001415889-24-000608
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

KNSA